BioRestorative Therapies (BRTX) Competitors

P3 Health Partners (NASDAQ:PIII) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.

Does the MarketBeat Community prefer PIII or BRTX?

P3 Health Partners received 3 more outperform votes than BioRestorative Therapies when rated by MarketBeat users. However, 100.00% of users gave BioRestorative Therapies an outperform vote while only 31.25% of users gave P3 Health Partners an outperform vote.

Company	Underperform	Outperform
P3 Health Partners	Outperform Votes 5 31.25%	Underperform Votes 11 68.75%
BioRestorative Therapies	Outperform Votes 2 100.00%	Underperform Votes No Votes

Is PIII or BRTX more profitable?

P3 Health Partners has a net margin of -6.95% compared to BioRestorative Therapies' net margin of -2,697.08%. P3 Health Partners' return on equity of -71.31% beat BioRestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.95%	-71.31%	-11.93%
BioRestorative Therapies	-2,697.08%	-98.49%	-75.23%

Do insiders & institutionals believe in PIII or BRTX?

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are held by institutional investors. 17.8% of P3 Health Partners shares are held by insiders. Comparatively, 25.5% of BioRestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts prefer PIII or BRTX?

P3 Health Partners presently has a consensus target price of $16.25, indicating a potential upside of 152.37%. BioRestorative Therapies has a consensus target price of $18.00, indicating a potential upside of 971.43%. Given BioRestorative Therapies' stronger consensus rating and higher probable upside, analysts plainly believe BioRestorative Therapies is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioRestorative Therapies	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor PIII or BRTX?

In the previous week, BioRestorative Therapies had 4 more articles in the media than P3 Health Partners. MarketBeat recorded 5 mentions for BioRestorative Therapies and 1 mentions for P3 Health Partners. BioRestorative Therapies' average media sentiment score of 0.76 beat P3 Health Partners' score of 0.44 indicating that BioRestorative Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Neutral
BioRestorative Therapies	Positive

Which has stronger earnings & valuation, PIII or BRTX?

BioRestorative Therapies has lower revenue, but higher earnings than P3 Health Partners. BioRestorative Therapies is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.49B	0.03	-$57.77M	-$47.28	-0.14
BioRestorative Therapies	$391K	32.25	-$14.41M	-$1.47	-1.14

Which has more volatility and risk, PIII or BRTX?

P3 Health Partners has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 76.75, suggesting that its share price is 7,575% more volatile than the S&P 500.

Summary

BioRestorative Therapies beats P3 Health Partners on 12 of the 17 factors compared between the two stocks.